Plain-English translation of NCT02919644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called autologous dendritic cell vaccination, which uses your own immune cells combined with material from your removed tumor to create a personalized vaccine. The goal is to train your immune system to recognize and fight any remaining cancer cells after surgery. This vaccine is given alongside a medication called Interleukin-2 (IL-2) to boost the immune response.
Even after successful surgery to remove advanced colorectal cancer, some patients experience cancer recurrence because microscopic cancer cells may remain in the body. This trial is exploring whether this personalized vaccine can help your immune system find and destroy those remaining cells, potentially improving long-term survival.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the personalized vaccine under your skin, followed by five daily injections of Interleukin-2. The study is designed in two stages: first, 7 patients will be enrolled to test safety and immune response; if results are promising, an additional 12 patients will join. Throughout the trial, you will have blood tests and imaging scans to monitor your immune response and overall health, and researchers will track whether the cancer returns and how long you survive.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
Italy